X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ALEMBIC LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ALEMBIC LTD DR. REDDYS LAB/
ALEMBIC LTD
 
P/E (TTM) x 41.8 56.7 73.7% View Chart
P/BV x 3.2 3.2 100.0% View Chart
Dividend Yield % 0.8 0.4 240.9%  

Financials

 DR. REDDYS LAB   ALEMBIC LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
ALEMBIC LTD
Mar-16
DR. REDDYS LAB/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs3,39753 6,433.1%   
Low Rs2,56029 8,737.2%   
Sales per share (Unadj.) Rs856.54.7 18,148.0%  
Earnings per share (Unadj.) Rs78.08.8 888.6%  
Cash flow per share (Unadj.) Rs139.99.0 1,553.8%  
Dividends per share (Unadj.) Rs20.000.15 13,333.3%  
Dividend yield (eoy) %0.70.4 183.8%  
Book value per share (Unadj.) Rs739.827.7 2,668.3%  
Shares outstanding (eoy) m165.74267.03 62.1%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.58.7 40.0%   
Avg P/E ratio x38.24.7 816.5%  
P/CF ratio (eoy) x21.34.6 466.9%  
Price / Book Value ratio x4.01.5 271.9%  
Dividend payout %25.71.7 1,500.5%   
Avg Mkt Cap Rs m493,63210,962 4,503.3%   
No. of employees `00022.7NA-   
Total wages/salary Rs m31,068238 13,053.8%   
Avg. sales/employee Rs Th6,259.0NM-  
Avg. wages/employee Rs Th1,369.8NM-  
Avg. net profit/employee Rs Th569.7NM-  
INCOME DATA
Net Sales Rs m141,9611,260 11,264.1%  
Other income Rs m1,715264 650.1%   
Total revenues Rs m143,6761,524 9,426.9%   
Gross profit Rs m24,72283 29,857.5%  
Depreciation Rs m10,26661 16,719.9%   
Interest Rs m6340 211,333.3%   
Profit before tax Rs m15,537285 5,453.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m3492,096 16.6%   
Extraordinary Inc (Exp) Rs m0-32 0.0%   
Tax Rs m2,9656 48,606.6%   
Profit after tax Rs m12,9212,343 551.5%  
Gross profit margin %17.46.6 265.1%  
Effective tax rate %19.12.1 891.3%   
Net profit margin %9.1185.9 4.9%  
BALANCE SHEET DATA
Current assets Rs m96,8371,689 5,734.1%   
Current liabilities Rs m84,199486 17,317.8%   
Net working cap to sales %8.995.4 9.3%  
Current ratio x1.23.5 33.1%  
Inventory Days Days73217 33.8%  
Debtors Days Days9881 120.5%  
Net fixed assets Rs m102,5521,624 6,314.4%   
Share capital Rs m829534 155.2%   
"Free" reserves Rs m121,7925,960 2,043.4%   
Net worth Rs m122,6217,404 1,656.2%   
Long term debt Rs m5,449104 5,224.4%   
Total assets Rs m218,1658,010 2,723.6%  
Interest coverage x25.5950.7 2.7%   
Debt to equity ratio x00 315.4%  
Sales to assets ratio x0.70.2 413.6%   
Return on assets %6.229.3 21.2%  
Return on equity %10.531.6 33.3%  
Return on capital %12.931.3 41.2%  
Exports to sales %54.62.9 1,855.0%   
Imports to sales %9.428.9 32.4%   
Exports (fob) Rs m77,52037 208,948.8%   
Imports (cif) Rs m13,274364 3,649.8%   
Fx inflow Rs m81,67037 220,134.8%   
Fx outflow Rs m26,355365 7,221.7%   
Net fx Rs m55,315-328 -16,872.6%   
CASH FLOW
From Operations Rs m21,444346 6,204.9%  
From Investments Rs m-18,404-48 38,663.9%  
From Financial Activity Rs m-3,692-301 1,226.6%  
Net Cashflow Rs m-1,144-3 38,133.3%  

Share Holding

Indian Promoters % 25.5 64.0 39.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 0.2 2,700.0%  
FIIs % 35.3 9.7 363.9%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 26.1 58.6%  
Shareholders   75,885 54,701 138.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  NOVARTIS  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 20, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS